货号:A131621 同义名: 埃替格韦 / GS-9137;JTK-303
Elvitegravir is a quinolinemonocarboxylic-acid HIV-1 integrase strand transfer inhibitor used to treat HIV infection. It is also a cytochrome P450 2C9 inducer.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Human immunodeficiency virus (HIV) encodes three enzymes, reverse transcriptase (RT), protease (PR) and integrase (IN), each of which play important roles in viral replicationElvitegravir: An emerging HIV integrase inhibitor https://www.researchgate.net/publication/244934621_Elvitegravir_An_emerging_HIV_integrase_inhibitor. Elvitegravir (GS-9137) is a HIV-1 integrase strand transfer inhibitor, with IC50 of 0.7 nM, 2.8 nM and 1.4 nM for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD, respectively[2]. It is also a cytochrome P450 2C9 inducer. Elvitegravir has been developed for treatment of HIV-1 infection. HIV-infected patients were treated with 200 - 800 mg Elvitegravir once daily or 50 mg daily coadministered with ritonavir and it was showed that Elvitegravir achieve Cmax within 3–4 h and the half-life of Elvitegravir was approximately 3 h and was increased to approximately 9 h when coadministered with ritonavir[1]. Elvitegravir suppressed the replication of MLV and primate retrovirus SIV infection with EC50 values of 5.8 nM and 0.5 nM, respectively[2]. Recently, it was found that Elvitegravir inhibits 2019-novel coronavirus in vitro. |
细胞系 | 浓度 | 检测类型 | 检测时间 | 活动说明 | 数据源 |
human C8166 cells | Function assay | Antiviral activity against HIV1 LAI 3B infected in human C8166 cells assessed as protection against virus-induced cytopathic effect by MTT assay, EC50=0.21 nM | 21763149 | ||
human MT4 cells | Cytotoxicity assay | Cytotoxicity against human MT4 cells by MTT assay, CC50=1.15 μM | 18665580 | ||
MT4 cells | Function assay | Antiviral activity against HIV1 3B in MT4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay, EC50=0.37 nM | 18665580 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00950859 | Infection, Human Immunodeficie... 展开 >>ncy Virus 收起 << | Phase 2 | Completed | - | - |
NCT01815736 | - | Active, not recruiting | - | - | |
NCT00950859 | - | Completed | - | - | |
计算器 | ||||
存储液制备 | 1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.23mL 0.45mL 0.22mL |
11.16mL 2.23mL 1.12mL |
22.33mL 4.47mL 2.23mL |
CAS号 | 697761-98-1 |
分子式 | C23H23ClFNO5 |
分子量 | 447.884 |
别名 | 埃替格韦 ;GS-9137;JTK-303;brand name: Stribild;EVG;D06677 |
运输 | 蓝冰 |
存储条件 |
液体 -20°C:3-6个月-80°C:12个月 粉末 Keep in dark place,Inert atmosphere,Room temperature |
溶解度 |
DMSO: 250 mg/mL(558.18 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO |
动物实验配方 |